Loading stock data…
PBYI
$7.49-0.02 (-0.27%)
Market ClosedLast close May 1
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Puma Biotechnology, Inc. in the Healthcare sector is trading at $7.49. The stock is currently near its 52-week high of $7.90, remaining 32.8% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why PBYI maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.49
Potential Upside
87.7%
Whystock Fair Value$14.06
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Hold
Mean target$5.00-33.2%
Range$5.00 – $5.00
Fundamentals
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$376.49M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
12.13
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.18
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.87%
Volume
Today's trading volume
160,526
Recent News
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
US Market's Hidden Gems: 3 Undiscovered Small Caps with Strong Potential
The United States market has shown impressive momentum, with a 4.4% increase over the last week and a remarkable 32% gain over the past year, while earnings are projected to grow by 16% annually. In this dynamic environment, identifying small-cap stocks with strong potential can offer unique opportunities for investors seeking to capitalize on emerging growth stories within the market.
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
PBYI stock drops over 9% as weak 2026 revenue guidance and heavy reliance on Nerlynx raise concerns despite modest sales growth.